Explore

Trendline Trendline
Clinical Trials Face Recruitment Challenges, Impacting Drug Development

Clinical Trials Face Recruitment Challenges, Impacting Drug Development

Clinical Trials Face Recruitment Challenges, Impacting Drug Development
Trendline Trendline
Fulcrum Therapeutics Halts Development of Sickle Cell Drug Pociredir Amid Safety Concerns

Fulcrum Therapeutics Halts Development of Sickle Cell Drug Pociredir Amid Safety Concerns

Fulcrum Therapeutics Halts Development of Sickle Cell Drug Pociredir Amid Safety Concerns
Rapid Read Rapid Read
Advancements in Lupus Treatment Unveiled at EULAR Conference

Advancements in Lupus Treatment Unveiled at EULAR Conference

The European Alliance of Associations for Rheumatology (EULAR) conference in London showcased promising new treatments for systemic lupus erythematosus (SLE). Johnson & Johnson's nipocalimab, Biogen and UCB's dapirolizumab pegol, and Merck KGaA's enpatoran are among the drugs showing potential in clinical trials. Nipocalimab, an FcRn inhibitor, demonstrated significant disease activity reduction in the JASMINE study. Dapirolizumab pegol reduced disease flares in the PHOENYCS GO trial, while enpatoran showed long-term benefits in the WILLOW study. These developments offer hope for more effective SLE treatments, a condition affecting millions worldwide.
Trendline Trendline
Aurinia Pharmaceuticals Reports LUPKYNIS Reduces Renal-Related Risks in Lupus Nephritis Patients

Aurinia Pharmaceuticals Reports LUPKYNIS Reduces Renal-Related Risks in Lupus Nephritis Patients

Aurinia Pharmaceuticals Reports LUPKYNIS Reduces Renal-Related Risks in Lupus Nephritis Patients
Trendline Trendline
Novellia Secures $18M Series A to Enhance Patient-Powered Data Platform

Novellia Secures $18M Series A to Enhance Patient-Powered Data Platform

Novellia Secures $18M Series A to Enhance Patient-Powered Data Platform
Rapid Read Rapid Read
Lundbeck Unveils New Migraine Treatment Data at American Headache Society Meeting

Lundbeck Unveils New Migraine Treatment Data at American Headache Society Meeting

Lundbeck US, a subsidiary of H. Lundbeck A/S, presented new data on its migraine treatment VYEPTI® (eptinezumab-jjmr) at the American Headache Society's 68th Annual Scientific Meeting in Orlando, Florida. The data includes findings from several trials, such as INFUSE, DELIVER, SUNSET, and RESOLUTION, which focus on the effectiveness of VYEPTI in treating migraine-related cognitive symptoms and headache hours. Additionally, new phase 2b data on bocunebart, an investigational drug targeting PACAP for migraine prevention, was also shared. VYEPTI is a monoclonal antibody designed for intravenous infusion to prevent migraines in adults. The presentations highlighted the drug's real-world effectiveness and its impact on cognitive symptoms, as well as the potential of bocunebart as a preventive treatment for severe migraines.
Rapid Read Rapid Read
FDA Issues Guidance to Accelerate Cell and Gene Therapy Development

FDA Issues Guidance to Accelerate Cell and Gene Therapy Development

The FDA has released draft guidance aimed at expediting the development of cell and gene therapies (CGT) by allowing developers to utilize existing scientific knowledge to streamline regulatory submissions. This initiative is part of a broader effort by the FDA to reduce barriers for CGT sponsors, particularly for diseases with limited treatment options. The guidance encourages the use of publicly available data and established knowledge, such as chemistry, manufacturing, and controls (CMC) data, to facilitate faster approval processes. The FDA's acting director of the Center for Biologics Evaluation and Research, Karim Mikhail, emphasized the importance of this guidance in delivering safe and effective therapies to patients with rare and life-threatening diseases.
Rapid Read Rapid Read
GLP-1 Drugs Show Promise in Reducing Addiction Risks

GLP-1 Drugs Show Promise in Reducing Addiction Risks

A study by Washington University School of Medicine in St. Louis has found that GLP-1 drugs, commonly used for type 2 diabetes and obesity, may also help prevent and treat addiction. The research, published in The BMJ, indicates that these medications are associated with lower risks of developing substance use disorders and fewer overdoses among users. The study analyzed health records from over 600,000 U.S. veterans and found that those taking GLP-1 drugs had a reduced risk of addiction-related emergencies and deaths.
Reuters Reuters
US FDA to review AI-based tool to predict drug-related liver damage

US FDA to review AI-based tool to predict drug-related liver damage

June 3 (Reuters) - The U.S. FDA's Center for Drug Evaluation and Research said on Wednesday it has accepted a letter of intent for an artificial intelligence-based drug development tool designed to help predict drug-induced liver injury.
Rapid Read Rapid Read
Penn Medicine Research Suggests Weight Loss Drugs May Prevent Breast Cancer

Penn Medicine Research Suggests Weight Loss Drugs May Prevent Breast Cancer

Preliminary research from Penn Medicine indicates that popular weight loss drugs, including Ozempic and Wegovy, may have the potential to prevent breast cancer. The study, led by Penn Medicine researchers, suggests that these medications could play a role in reducing breast cancer risk, although the exact mechanisms remain unclear. The research is still in its early stages, and while the findings are promising, they require further investigation to confirm the potential benefits and understand how these drugs might contribute to cancer prevention.
Trendline Trendline
Corrixr Therapeutics Appoints New CEO to Advance Cancer Treatment Program

Corrixr Therapeutics Appoints New CEO to Advance Cancer Treatment Program

Corrixr Therapeutics Appoints New CEO to Advance Cancer Treatment Program
Rapid Read Rapid Read
Pediatric Experts Identify Key Research Areas to Advance Child Health

Pediatric Experts Identify Key Research Areas to Advance Child Health

A group of pediatric research leaders has identified ten promising areas of research that are expected to shape the future of child health over the next decade. These areas include gene therapy, mental health, immunizations, and technology-based solutions like artificial intelligence. The study, published in the journal Pediatric Research, highlights the importance of sustaining investment in these fields to improve diagnosis, treatment, and overall health outcomes for children. The research emphasizes the need for explainable and ethically governed AI tools, as well as the impact of social determinants on child health.